Axis-Shield, the international in vitro diagnostics company, today announces the launch of a test for D-dimer to run on the widely-placed AxSYM automated immunoassay system marketed by Abbott Laboratories. D-dimer is an important blood coagulation marker which is raised in deep vein thrombosis (DVT) and pulmonary embolism (PE). These are serious and relatively common clotting conditions that contribute to patient morbidity and mortality, with substantial costs to healthcare systems in the developed world, where the incidence is around 1:1000. The AxSYM D-dimer test has a negative predictive value greater than 98%, giving it high utility in ruling out DVT and PE.
Axis-Shield
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
J&J Enters Robotic Surgery Market
The companies entered into a cooperative agreement in May 2018 to combine J&J’s NeuWave system with the Monarch platform.
CDER’s Regulatory Modernization Will Peak in 2019, Woodcock Says
The center expects to have its proposed reorganization approved by HHS towards the end of FY 2019.
FDAnews Device Daily Bulletin
AXIS-SHIELD ANNOUNCES LAUNCH OF FIRST ASSAY UNDER AXSYM XTRA PROGRAMME
June 1, 2006
